Bolt Biotherapeutics (BOLT) — Financial Flexibility Index

Latest as of December 2025: -0.24x

Bolt Biotherapeutics (BOLT) has a Financial Flexibility Index of -0.24x as of December 2025. Free cash flow of $-7.16 Million (operating CF $-7.16 Million minus capex $0.00) represents 0% of total liabilities ($30.24 Million). Also explore BOLT year-over-year net asset growth to track the company's year-over-year net asset growth rate.

Financial Flexibility Index

-0.24x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-7.16 Million
Operating CF − Capex

Total Liabilities

$30.24 Million
USD

Capital Expenditures

$0.00
USD

Bolt Biotherapeutics Financial Flexibility Index (2018–2025)

Historical Financial Flexibility Index trend for Bolt Biotherapeutics across 8 annual periods. Check Bolt Biotherapeutics PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Annual Financial Flexibility Index for Bolt Biotherapeutics (2018–2025)

Year-by-year free cash flow to debt coverage for Bolt Biotherapeutics. For the full company profile including market capitalisation, see BOLT market cap overview.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2025 -1.32x $-39.78 Million $-39.85 Million $30.24 Million ▲ +8.9%
2024 -1.44x $-61.25 Million $-61.29 Million $42.43 Million ▲ +2.0%
2023 -1.47x $-69.32 Million $-69.53 Million $47.04 Million ▼ -11.3%
2022 -1.32x $-74.55 Million $-76.50 Million $56.30 Million ▼ -39.4%
2021 -0.95x $-54.73 Million $-57.07 Million $57.60 Million ▼ -226.8%
2020 -0.29x $-44.05 Million $-47.31 Million $151.49 Million ▼ -6.1%
2019 -0.27x $-25.84 Million $-26.34 Million $94.29 Million ▲ +8.7%
2018 -0.30x $-9.58 Million $-9.87 Million $31.92 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities